GlassScriptPhysician profile
Guruprasad Srinivas
NPI 1821318742
$6,837.95
in general payments reported to CMS, 2019-2025
27 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $402 · 2021: $1,827 · 2022: $509 · 2023: $1,636 · 2024: $1,364 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,121.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,072.83 | 2019-2025 | Avvigo Guidance System, Varithena Administration Pack, Watchman Access System |
| Janssen Pharmaceuticals, INC | $965.22 | 2019-2024 | Xarelto |
| Abbott Laboratories | $671.01 | 2019-2023 | Aveir |
| Medtronic, INC. | $444.90 | 2021-2025 | Cobalt Dr Mri Surescan, Symplicity G3, Azure Xt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $418.44 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $366.39 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $357.39 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.50 | 2020-2024 | Jardiance |
| Medtronic Vascular, INC. | $300.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $293.00 | 2023-2024 | Camzyos, Eliquis |
| Amgen INC. | $215.02 | 2019-2024 | Repatha |
| Scpharmaceuticals INC. | $206.93 | 2023-2024 | |
| Lilly USA, LLC | $145.61 | 2024 | Mounjaro, Zepbound |
| Tactile Systems Technology INC | $142.11 | 2024 | Flexitouch Plus, Entre Plus |
| Lexicon Pharmaceuticals, INC. | $134.87 | 2023-2024 | Inpefa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.20 | 2024 | |
| Alnylam Pharmaceuticals INC. | $118.39 | 2021 | |
| Shockwave Medical, INC | $114.31 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $71.36 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $61.62 | 2024 | Arcalyst |
| Philips North America LLC | $59.19 | 2019 | |
| Edwards Lifesciences Corporation | $28.96 | 2024 | Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $23.97 | 2023 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $18.44 | 2023 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $18.41 | 2023 | |
| Novo Nordisk INC | $13.85 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guruprasad Srinivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.